-
J Clin Oncol: Efficacy of Ciltacabtagene autoleucel in adult patients with relapsed or refractory multiple myeloma in our country
Time of Update: 2022-10-25
S. FDA approved Cilta-cel for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received ≥ 4-line therapy, including proteasome inhibitors [PI], immunomodulators [IMiD], and anti-CD38 monoclonal antibodies.
-
J Clin Oncol: Cediranib in combination with olaparib for metastatic castration-resistant prostate cancer
Time of Update: 2022-10-25
In summary, Cediranib combined with olaparib significantly prolongs the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer compared with olaparib alone.
In summary, Cediranib combined with olaparib significantly prolongs the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer compared with olaparib alone.
-
This article summarizes the current status of first-line immunotherapy for non-small cell lung cancer
Time of Update: 2022-10-25
First-line immunomonotherapy1PD-1 inhibitors The KEYNOTE-024 study showed that in patients with advanced NSCLC with PD-L1 expression ≥ 50% and ALK or EGFR negative, the PD-1 inhibitor pembrolizumab had significantly longer progression-free survival (PFS) and overall survival (OS) and fewer adverse events (AEs) compared with platinum-based chemotherapy.
-
BioNTech's next battle with Moderna: mRNA oncology vaccines
Time of Update: 2022-10-25
com——List of recent popular events——On October 25, the difficulties of the large-scale production process of exosomes were analyzedOctober 20, 2022 /eMedClub News/--In recent years, the help of new crown vaccines has made mRNA technology more and more mature, Moderna With BioNTech have intensified the layout of mRNA cancer vaccines.
-
Colorectal cancer treatment: FOLFOXIRI + panituzumab vs. FOLFOX + panitumab
Time of Update: 2022-10-25
Studies have shown that initial treatment with the triple regimen FOLFOXIRI + bevacizumab improves response rates and survival compared with dual chemotherapy (J Clin Oncol 2020; 38:3314）。Italian researchers conducted a randomized phase 3 trial of patients with advanced RAS and BRAF wild-type colorectal cancer that compared dual mFOLFOX + panitumab with triple mFOLFOXIRI + panitumab.
-
Eur Urol: In patients with non-muscle-invasive bladder cancer, T cell depletion and elevated levels of tumor DNA in the urine are associated with BCG treatment failure
Time of Update: 2022-10-25
In patients with high-risk non-muscle-invasive bladder cancer, the functional status and tumor characteristics of immune cells in the tumor microenvironment may explain the failure of BCG (NMIBC) therapy.
-
Founder of BioNTech: mRNA cancer vaccines have achieved a breakthrough and will be available by 2030
Time of Update: 2022-10-25
Written byWang CongEditorWang Duoyu TypesettingShui Chengwen A few days ago, mRNA vaccine giant BioNTech founders Uğur Şahin and Özlem Türeci In an interview with BBC, the couple said that BioNTech ha
-
Blood: Progression and prognosis of monoclonal B lymphocytosis
Time of Update: 2022-10-25
Slager screen MBL cases and assess their correlation with future hematological malignancies and overall survival (OS).
Slager screen MBL cases and assess their correlation with future hematological malignancies and overall survival (OS).
Slager screen MBL cases and assess their correlation with future hematological malignancies and overall survival (OS).
-
K-Medicine's "Pride and Hao"
Time of Update: 2022-10-25
*For medical professionals onlyRegardless of success or failure and cost, it attracts the pride and pride of countless heroesEntering the golden autumn October, China's advanced liver cancer immunothe
-
Cell Metabo: The team of Zhimin Shao and Yizhou Jiang found that the heterogeneity of iron death in triple-negative breast cancer may be associated with immunotherapy
Time of Update: 2022-10-25
" Professor Shao Zhimin said that "iron death" is a regulatory cell death method closely related to metabolism discovered in recent years, which is active in the field of tumor research, and the team tried to start from this perspective to discover a new breakthrough in the treatment of triple-negative breast cancer.
-
Express to break through the dilemma of EGFR drug resistance in non-small cell lung cancer! AstraZeneca reached a clinical cooperation agreement
Time of Update: 2022-10-25
The collaboration will evaluate the efficacy of AstraZeneca's third representative, the skin growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib (trade name: Teressa), in combination with Ikena's IK-930 to treat patients with EGFR-mutated non-small cell lung cancer (NSCLC).
-
Eur Urol Oncol: How effective is neoadjuvant 177Lu-PSMA-I&T radionuclide therapy in patients with high-risk prostate cancer?
Time of Update: 2022-10-25
Recently, researchers from Israel published an article in Eur Urol Oncol to evaluate whether lutetium-177 prostate-specific membrane antigen radioligand (LuPSMA) can be safely used in patients with HRLPC prior to robotic-assisted radical prostatectomy (RARP) and elaborated on immediate oncology results.
-
Recent advances in immunotherapy for myelodysplastic syndromes from an international perspective
Time of Update: 2022-10-25
8-NR); the investigators considered the significant efficacy of the combination regimen in TP53 mutation subsets, possibly because macrophages do not depend on p53 activity 。 Early data from this study were so good that they prompted a Phase 3 randomized clinical trial (ENHANCE study) of azacitidine plus magrolimab versus azacitidine monotherapy for the treatment of naïve high-risk MDS.
-
Targeted drugs for the driving gene of lung squamous cell carcinoma are finally on the scene!
Time of Update: 2022-10-25
, Targeting NFE2L2/ KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228, Journal of Thoracic Oncology (2022)References: Paik PK, et al.
-
Cell Metabolism: Get more progress! Shao Zhimin and other teams at Fudan University found that iron death plays an important role in triple-negative breast cancer
Time of Update: 2022-10-25
On October 17, 2022, Shao Zhimin, Jiang Yizhou and Xiao Yi of Fudan University jointly published a research paper entitled "Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy" online at Cell Metabolism , which integrated multiomics data from the TNBC cohort (n=465) to develop an atlas of iron death.
-
Team of Lin Jun of Changchun Institute of Applied Chemistry/Li Chunxia of Shandong University AS: Noble metal nanoenzyme AuPtAg-GOx induces synergistic tumor immunotherapy induced by starvation therapy to enhance mild photothermal therapy
Time of Update: 2022-10-25
WILEYPaper Information:A Noble AuPtAg-GOx Nanozyme for Synergistic Tumor Immunotherapy Induced by Starvation Therapy-Augmented Mild Photothermal TherapyMan Wang, Mengyu Chang, Pan Zheng, Qianqian Sun, Guangqiang Wang, Jun Lin,* and Chunxia Li*Advanced ScienceDOI: 10.
-
Cell metabo: a review of the cancer metabolic blueprint
Time of Update: 2022-10-25
In addition, some types of transformed cells adapt to lower levels of nitrogenous nutrient consumption in their environment (which are in high demand in proliferating cells due to nitrogen's role in building proteins and nucleic acids) by utilizing free ammonium and remodeling metabolism to preferentially use nitrogen donors for nucleotide and non-essential amino acid synthesis.
-
Advantages of peripheral blood stem cell transplantation over unrelated donor bone marrow transplantation in the prognosis of adults with acute myeloid leukemia
Time of Update: 2022-10-25
GuideIncluding acute leukemia and malignant lymphoma, allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure patients with hematologic malignancies. When there is no suitable related
-
The country's first real-world general population colorectal cancer screening prospective clinical results were released, and early screening tests were upgraded
Time of Update: 2022-10-25
Recently, Shenzhen Jinbaihui Biotechnology Co. , Ltd. announced the completion of China's first real-world general population colorectal cancer screening 10,000 prospective clinical trials: "Ruichangt
-
Cancers: CAR-T and CAR-NK solid tumor targeting strategies
Time of Update: 2022-10-25
The tumor local expression of CXCL11 by oncolytic vaccinia virus in a mouse model of mesothelioma successfully increased the transport of endogenous cytotoxic T lymphocytes to tumors and induced systemic anti-tumor immunity, highlighting the importance of CXCR3 axis for lymphocyte migration.
